Pfiz­er and BioN­Tech roll out new da­ta for their bi­va­lent boost­er against new­er Omi­cron vari­ants

As Pfiz­er and BioN­Tech tout the ef­fec­tive­ness of their bi­va­lent boost­er against Omi­cron vari­ants such as BA.4 and BA.5, more Covid-19 vari­ants have been creep­ing up on the gen­er­al pub­lic. Now the part­ners are lift­ing the cov­er on new da­ta show­ing its ef­fec­tive­ness against the new­er vari­ants of the virus.

On Fri­day, Pfiz­er and BioN­Tech re­port­ed new re­sults an­a­lyz­ing the im­mune re­sponse in­duced by the bi­va­lent Covid-19 vac­cine against the new­er “sub­lin­eages” in­clud­ing BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1, with Pfiz­er and BioN­Tech stat­ing that the vac­cine “elic­its a greater in­crease in neu­tral­iz­ing an­ti­body titers” than the orig­i­nal vac­cine against these sub­lin­eages and pro­vid­ing over­all pro­tec­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.